105 related articles for article (PubMed ID: 12084457)
1. Self-association and unique DNA binding properties of the anti-cancer agent TAS-103, a dual inhibitor of topoisomerases I and II.
Ishida K; Asao T
Biochim Biophys Acta; 2002 Jul; 1587(2-3):155-63. PubMed ID: 12084457
[TBL] [Abstract][Full Text] [Related]
2. Interaction of a novel antitumor agent TAS-103 with DNA.
Ishida K; Asao T
Nucleic Acids Symp Ser; 1999; (42):129-30. PubMed ID: 10780413
[TBL] [Abstract][Full Text] [Related]
3. An investigation into the formation of N- [2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and 6-[2-(dimethylamino)ethylamino]- 3-hydroxy-7H-indeno[2, 1-C]quinolin-7-one dihydrochloride (TAS-103) stabilised DNA topoisomerase I and II cleavable complexes in human leukaemia cells.
Padget K; Stewart A; Charlton P; Tilby MJ; Austin CA
Biochem Pharmacol; 2000 Sep; 60(6):817-21. PubMed ID: 10930536
[TBL] [Abstract][Full Text] [Related]
4. Establishment and characterization of 6-[[2-(Dimethylamino)ethyl]amino]-3-hydroxy-7H-indeno[2,1-c]quinolin-7-one dihydrochloride (TAS-103)-resistant cell lines.
Aoyagi Y; Kobunai T; Utsugi T; Wierzba K; Yamada Y
Jpn J Cancer Res; 2000 May; 91(5):543-50. PubMed ID: 10835500
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and II.
Utsugi T; Aoyagi K; Asao T; Okazaki S; Aoyagi Y; Sano M; Wierzba K; Yamada Y
Jpn J Cancer Res; 1997 Oct; 88(10):992-1002. PubMed ID: 9414662
[TBL] [Abstract][Full Text] [Related]
6. A dual topoisomerase inhibitor, TAS-103, induces apoptosis in human cancer cells.
Ohyama T; Li Y; Utsugi T; Irie S; Yamada Y; Sato T
Jpn J Cancer Res; 1999 Jun; 90(6):691-8. PubMed ID: 10429663
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of action of the dual topoisomerase-I and -II inhibitor TAS-103 and activity against (multi)drug resistant cells.
Minderman H; Wrzosek C; Cao S; Utsugi T; Kobunai T; Yamada Y; Rustum YM
Cancer Chemother Pharmacol; 2000; 45(1):78-84. PubMed ID: 10647506
[TBL] [Abstract][Full Text] [Related]
8. In vitro antitumor activity of TAS-103 against freshly-isolated human colorectal cancer.
Tsunoda T; Tanimura H; Yamaue H; Ishimoto K; Kobunai T; Yamada Y
Anticancer Res; 2001; 21(6A):3897-902. PubMed ID: 11911266
[TBL] [Abstract][Full Text] [Related]
9. DNA topoisomerases as targets for the anticancer drug TAS-103: primary cellular target and DNA cleavage enhancement.
Byl JA; Fortune JM; Burden DA; Nitiss JL; Utsugi T; Yamada Y; Osheroff N
Biochemistry; 1999 Nov; 38(47):15573-9. PubMed ID: 10569941
[TBL] [Abstract][Full Text] [Related]
10. DNA topoisomerases as targets for the anticancer drug TAS-103: DNA interactions and topoisomerase catalytic inhibition.
Fortune JM; Velea L; Graves DE; Utsugi T; Yamada Y; Osheroff N
Biochemistry; 1999 Nov; 38(47):15580-6. PubMed ID: 10569942
[TBL] [Abstract][Full Text] [Related]
11. Promising antitumor activity of a novel quinoline derivative, TAS-103, against fresh clinical specimens of eight types of tumors measured by flow cytometric DNA analysis.
Fujimoto S
Biol Pharm Bull; 2007 Oct; 30(10):1923-9. PubMed ID: 17917263
[TBL] [Abstract][Full Text] [Related]
12. Combination effects of TAS-103, a novel dual topoisomerase I and II inhibitor, with other anticancer agents on human small cell lung cancer cells.
Sunami T; Nishio K; Kanzawa F; Fukuoka K; Kudoh S; Yoshikawa J; Saijo N
Cancer Chemother Pharmacol; 1999; 43(5):394-401. PubMed ID: 10100595
[TBL] [Abstract][Full Text] [Related]
13. Metabolism and urinary excretion of a new quinoline anticancer drug, TAS-103, in humans.
Azuma R; Saeki M; Yamamoto Y; Hagiwara Y; Grochow LB; Donehower RC
Xenobiotica; 2002 Jan; 32(1):63-72. PubMed ID: 11820510
[TBL] [Abstract][Full Text] [Related]
14. In vitro antitumor activity of TAS-103, a novel quinoline derivative that targets topoisomerases I and II.
Aoyagi Y; Kobunai T; Utsugi T; Oh-hara T; Yamada Y
Jpn J Cancer Res; 1999 May; 90(5):578-87. PubMed ID: 10391099
[TBL] [Abstract][Full Text] [Related]
15. F 11782, a dual inhibitor of topoisomerases I and II with an original mechanism of action in vitro, and markedly superior in vivo antitumour activity, relative to three other dual topoisomerase inhibitors, intoplicin, aclarubicin and TAS-103.
Etiévant C; Kruczynski A; Barret JM; Perrin D; van Hille B; Guminski Y; Hill BT
Cancer Chemother Pharmacol; 2000; 46(2):101-13. PubMed ID: 10972479
[TBL] [Abstract][Full Text] [Related]
16. A new mechanism of 6-((2-(dimethylamino)ethyl)amino)-3-hydroxy-7H-indeno(2,1-c)quinolin-7-one dihydrochloride (TAS-103) action discovered by target screening with drug-immobilized affinity beads.
Yoshida M; Kabe Y; Wada T; Asai A; Handa H
Mol Pharmacol; 2008 Mar; 73(3):987-94. PubMed ID: 18089836
[TBL] [Abstract][Full Text] [Related]
17. Molecular interactions of DNA-topoisomerase I and II inhibitor with DNA and topoisomerases and in ternary complexes: binding modes and biological effects for intoplicine derivatives.
Nabiev I; Chourpa I; Riou JF; Nguyen CH; Lavelle F; Manfait M
Biochemistry; 1994 Aug; 33(30):9013-23. PubMed ID: 8043587
[TBL] [Abstract][Full Text] [Related]
18. Cancer chemotherapy by liposomal 6-[12-(dimethylamino)ethyl]aminol-3-hydroxy-7H-indeno[2,1-clquinolin-7-one dihydrochloride (TAS-103), a novel anti-cancer agent.
Shimizu K; Takada M; Asai T; Kuromi K; Baba K; Oku N
Biol Pharm Bull; 2002 Oct; 25(10):1385-7. PubMed ID: 12392102
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of apoptosis induced by a new topoisomerase inhibitor through the generation of hydrogen peroxide.
Mizutani H; Tada-Oikawa S; Hiraku Y; Oikawa S; Kojima M; Kawanishi S
J Biol Chem; 2002 Aug; 277(34):30684-9. PubMed ID: 12068015
[TBL] [Abstract][Full Text] [Related]
20. Unique action determinants of double acting topoisomerase inhibitor, TAS-103.
Okamoto R; Takano H; Sekikawa T; Tanaka T; Toyada M; Ukon K; Tanimoto K; Kumazaki T; Nishiyama M
Int J Oncol; 2001 Nov; 19(5):921-7. PubMed ID: 11604989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
